Loading clinical trials...
Loading clinical trials...
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Conditions
Interventions
Obeticholic Acid
Locations
7
United States
Scripps Clinic
La Jolla, California, United States
University of California, Davis Medical Center
Sacramento, California, United States
University of Miami
Miami, Florida, United States
Indiana University Medical Center
Indianapolis, Indiana, United States
Beth Israel Medical Center
New York, New York, United States
McGuire DVAMC
Richmond, Virginia, United States
Start Date
December 3, 2013
Primary Completion Date
August 13, 2014
Completion Date
September 12, 2016
Last Updated
August 24, 2022
NCT04526665
NCT03301506
NCT03743272
NCT02846896
NCT03112681
NCT02963077
Lead Sponsor
Intercept Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions